Dermata Therapeutics Warrant Stock Current Valuation
| DRMAW Stock | USD 0.01 0.00 0.00% |
Valuation analysis of Dermata Therapeutics helps investors to measure Dermata Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -21.65 in 2024. Enterprise Value Multiple is likely to drop to -21.65 in 2024.
Overvalued
Today
Please note that Dermata Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Dermata Therapeutics is based on 3 months time horizon. Increasing Dermata Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Dermata stock is determined by what a typical buyer is willing to pay for full or partial control of Dermata Therapeutics Warrant. Since Dermata Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dermata Stock. However, Dermata Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0088 | Real 0.008085 | Hype 0.01 | Naive 0.007983 |
The intrinsic value of Dermata Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dermata Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dermata Therapeutics Warrant helps investors to forecast how Dermata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dermata Therapeutics more accurately as focusing exclusively on Dermata Therapeutics' fundamentals will not take into account other important factors: Dermata Therapeutics Warrant Company Current Valuation Analysis
Dermata Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Dermata Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Dermata Therapeutics is extremely important. It helps to project a fair market value of Dermata Stock properly, considering its historical fundamentals such as Current Valuation. Since Dermata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dermata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dermata Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Dermata Current Valuation Historical Pattern
Today, most investors in Dermata Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dermata Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dermata Therapeutics current valuation as a starting point in their analysis.
Dermata Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Dermata Therapeutics Warrant has a Current Valuation of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Dermata Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dermata Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics of similar companies.Dermata Therapeutics is currently under evaluation in current valuation category among its peers.
Dermata Fundamentals
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 | ||||
| Number Of Shares Shorted | 1.2 K | ||||
| EBITDA | 247.22 K | ||||
| Net Income | (7.79 M) | ||||
| Total Debt | 1.62 M | ||||
| Book Value Per Share | 24.25 X | ||||
| Cash Flow From Operations | (6.41 M) | ||||
| Earnings Per Share | (2.16) X | ||||
| Beta | 0.79 | ||||
| Total Asset | 7.98 M | ||||
| Retained Earnings | (53.39 M) | ||||
| Working Capital | 6.36 M | ||||
| Net Asset | 7.98 M |
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.